“Gereksiz” Acil Servis Başvuruları ve Aile Hekimliğinin Rolü
Synopsis
Some patients who attend the emergency department present with complaints that could be assessed in primary care. How many of these visits are considered “unnecessary” depends largely on the definition used, and existing classification methods are not a safe basis for redirecting patients away from the emergency department. The chapter examines why patients choose the emergency department, how the organization of primary care relates to emergency department use, and the evidence on interventions such as after-hours access, telephone triage and streaming of patients from the emergency department to primary care physicians. In international studies, continuity of care is the primary care feature most consistently associated with fewer emergency department visits. Findings on whether these interventions reduce the number of visits are inconsistent. National data, relevant regulations and patient studies from Türkiye are discussed separately. The final section recommends that emergency department staff also provide discharge information in writing and use the teach-back method to check that patients have understood it. For family medicine, regular follow-up by the patient’s own physician and timely access to that physician when needed appear to be important.
References
Chapman SA, Irwin ED, Beal AL, et al. Prothrombin complex concentrate versus standard therapies for INR reversal in trauma patients receiving warfarin. Annals of Pharmacotherapy. 2011;45(7–8):869–875. doi:10.1345/aph.1P605
Sarode R, Milling TJ Jr, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation. 2013;128(11):1234–1243. doi: 10.1111/tme.12621
Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action. Archives of Internal Medicine. 2007;167(13):1414–1419. doi:10.1001/archinte.167.13.1414
Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th edition. Chest. 2012;141(2 Suppl):e152S–e184S. doi:10.1378/chest.11-2295
Wang K, Zhang T, Rao J, et al. Drug–drug interactions induced by linderane based on mechanism-based inactivation of CYP2C9 and the molecular mechanisms. Bioorganic Chemistry. 2022;118:105478. doi:10.1016/j.bioorg.2021.105478
Lippi G, Favaloro EJ. Preanalytical issues in hemostasis and thrombosis testing. Methods in Molecular Biology. 2017;1646:29–42. doi:10.1007/978-1-4939-7196-1_2
Ansell J, Hirsh J, Hylek E, et al. Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):160S–198S. doi:10.1378/chest.08-0670
Berling I, Mostafa A, Grice JE, et al. Warfarin poisoning with delayed rebound toxicity. Journal of Emergency Medicine. 2017;52(2):194–196. doi:10.1016/j.jemermed.2016.05.068
Witt DM, Clark NP, Kaatz S, et al. Guidance for the practical management of warfarin therapy in the treatment of venous thromboembolism. Journal of Thrombosis and Thrombolysis. 2016;41(1):187–205. doi:10.1007/s11239-015-1319-y
Tomaselli GF, Mahaffey KW, Cuker A, et al. 2020 ACC expert consensus decision pathway on management of bleeding in patients on oral anticoagulants. Journal of the American College of Cardiology. 2020;76(5):594–622. doi:10.1016/j.jacc.2020.04.053
Milling TJ Jr, Pollack CV Jr. A review of guidelines on anticoagulation reversal across different clinical scenarios: Is there a general consensus? American Journal of Emergency Medicine. 2020;38(9):1890–1903. doi:10.1016/j.ajem.2020.05.086
Tran HA, Chunilal SD, Harper PL, et al. An update of consensus guidelines for warfarin reversal. Medical Journal of Australia. 2013;198(4):198–199. doi:10.5694/mja12.10614
Crowther MA, Ageno W, Garcia D, et al. Oral vitamin K versus placebo to correct excessive anticoagulation in patients receiving warfarin: a randomized trial. Annals of Internal Medicine. 2009;150(5):293–300. doi:10.7326/0003-4819-150-5-200903030-00005
